Canary Medical to Present Data at the AAOS 2021 Annual Meeting

Canary Medical is a medical data company focused on the development and commercialization of its patented implantable sensor technology.

Canary Medical today announced that it will present data in a podium presentation assessing Persona IQ® an investigational smart knee implant that combines Zimmer Biomet’s Persona® The Personalized Knee® with Canary Medical’s proprietary implantable canturioTM te tibial extension sensor technology, at the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting being held from August 31st to September 3rd in San Diego, CA. The canturioTM te tibial extension is currently under FDA review and is not available for commercial use or sale.

Cte Implant Knee Implant 1

Conference Details:

Conference: American Academy of Orthopaedic Surgeons (AAOS)
Paper Title: The Talking Knee Is a Reality: Remote Patient Monitoring Prosthesis for Total Knee Arthroplasty
Presenter: Fred D. Cushner, MD, FAAOS, Hospital for Special Surgery
Session: Adult Reconstruction Knee IV
Paper Number: 459
Date and Time: 9/2/2021, 9:00 AM (PT), Ballroom 6A

The presentation abstract will be available on the AAOS website on August 31st here. Canary Medical will also be showcasing its technologies at its booth #1025 in Hall B1 as well as in Zimmer Biomet’s booth #2535 in Hall C.

Canary Medical was conceived and created by a team of medical device developers with active implantable experience, clinician guidance, and IoT experts with the vision that (1) healthcare transformation requires better and cheaper healthcare data, (2) better monitoring and better data will produce better outcomes at lower costs, and (3) patients own their healthcare data and should be compensated for its use. Canary Medical’s patented implant and data management ecosystem technology provides the vehicle to implement its vision. Canary Medical is led by a team of experienced entrepreneurs, researchers and data scientists globally regarded for their expertise in medical device design, development and data informatics.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”